The 2026 GLP-1 landscape — every drug, every generation.
In ten years, obesity pharmacology has gone from "a few percentage points of weight loss" to "the most effective metabolic intervention ever made available." Here is the complete map — what is approved, what is filed, what is in trials, and how to think about which generation you are using.
Four generations of incretin therapy.
The simplest way to keep this field straight is by generation — defined by how many receptors a single molecule activates. Each new generation has produced more weight loss than the last:
- Generation 1: Single agonist (GLP-1). Semaglutide. ~14.9% mean weight loss in Phase 3.
- Generation 2: Dual agonist (GLP-1 + GIP). Tirzepatide. ~22.5% mean weight loss in Phase 3.
- Generation 3: Triple agonist (GLP-1 + GIP + glucagon). Retatrutide. ~28.7% mean weight loss in Phase 3 (TRIUMPH-4, December 2025).
- Generation 4: Combination and oral. CagriSema (semaglutide + cagrilintide amylin agonist), orforglipron (oral non-peptide GLP-1). Different mechanisms, different reasons to exist.
Semaglutide — the foundation.
Semaglutide
Ozempic (T2D), Wegovy (obesity), Rybelsus (oral, T2D). Same molecule, different brand names and indications. The drug that made GLP-1 a household word. Phase 3 STEP program produced ~14.9% mean weight loss at 68 weeks. The SELECT trial (2023) demonstrated a 20% reduction in major adverse cardiovascular events in patients with established cardiovascular disease — a uniquely strong evidence base that no other GLP-1 has yet matched.
Where semaglutide still wins in 2026: cardiovascular protection, oral formulation availability (Rybelsus), and lower cost in some payer scenarios. Where it loses: weight-loss efficacy versus tirzepatide.
Tirzepatide — the current standard.
Tirzepatide
Mounjaro (T2D), Zepbound (obesity, OSA). Adding the GIP receptor delivered ~22.5% mean weight loss in SURMOUNT-1 — and SURMOUNT-5 (NEJM 2025) confirmed superiority versus semaglutide head-to-head (20.2% vs. 13.7%). Tirzepatide also has the cleaner GI tolerability profile because GIP agonism modulates the nausea pathway.
In 2024, tirzepatide was added to the FDA's approved indication list for obstructive sleep apnea in adults with obesity — the first GLP-1/GIP to reach that indication. The cardiovascular outcomes trial SURPASS-CVOT is pending but expected to show CV benefit similar to (though not yet proven equal to) semaglutide.
Retatrutide — the headline drug.
Retatrutide (LY3437943)
The first triple agonist to reach Phase 3. TRIUMPH-4 (December 2025) produced 28.7% mean weight loss at the 12 mg dose over 68 weeks — the highest figure ever reported in a Phase 3 obesity trial. Adding the glucagon receptor turns up resting energy expenditure and lipolysis, which is what allows the additional weight loss.
Seven additional Phase 3 readouts are expected through 2026, including TRIUMPH-1 (the largest registration trial), TRIUMPH-2, and the cardiovascular outcomes trial. NDA submission is anticipated late 2026 with FDA approval likely in late 2027 or early 2028. Retatrutide is investigational as of May 2026 and is not legally compoundable in the U.S.
For the deep dive, read our Retatrutide 2026 article covering the Phase 3 program, mechanism, and FDA timeline.
The diversifying frontier.
Generation 4 is less about adding receptors and more about (a) different mechanisms, (b) different delivery formats, and (c) the maturation of the field beyond "more weight loss is always better."
CagriSema
Novo Nordisk's combination of semaglutide and cagrilintide (a long-acting amylin analog). Filed for FDA approval in December 2025, PDUFA date around October 2026 — making CagriSema the most likely new obesity drug to reach the market in 2026. Phase 3 REDEFINE results showed weight loss between semaglutide alone and tirzepatide alone, with potentially smoother appetite suppression because amylin and GLP-1 hit different satiety pathways.
Orforglipron
Eli Lilly's oral, non-peptide GLP-1. ATTAIN-1 (completed August 2025) showed 12.4% mean weight loss at 72 weeks. Significantly less weight loss than injectable competitors, but the format advantage is real: orforglipron is an oral pill that does not require the food/water timing restrictions that Rybelsus does. NDA filing anticipated in 2026.
For patients who refuse injections, orforglipron will be the first true oral option in this category.
Survodutide
Boehringer Ingelheim's GLP-1/glucagon dual agonist (notably without GIP). Phase 2 produced ~19% weight loss; Phase 3 SYNCHRONIZE program is ongoing with no efficacy readouts yet. The mechanistic interest is high because survodutide is studying whether you can replicate retatrutide-class weight loss without GIP — relevant if any GIP-related safety signal emerges in the broader class.
The full landscape, side-by-side.
| Drug | Mechanism | Phase 3 weight loss | FDA status |
|---|---|---|---|
| Semaglutide | GLP-1 | ~14.9% | Approved |
| Tirzepatide | GLP-1 + GIP | ~22.5% | Approved |
| CagriSema | GLP-1 + amylin | ~22.7% | Filed · PDUFA ~Oct 2026 |
| Survodutide | GLP-1 + glucagon | ~19% (Phase 2) | Phase 3 ongoing |
| Orforglipron | Oral GLP-1 (non-peptide) | ~12.4% | NDA expected 2026 |
| Retatrutide | GLP-1 + GIP + glucagon | ~28.7% | Phase 3 ongoing · NDA late 2026 |
Phase 3 figures are mean values from largest published trials; cross-trial comparisons should be interpreted with caution because populations and durations differ.
What this means for you.
- If you are starting in 2026: tirzepatide is the highest-efficacy approved option. Semaglutide is the choice when CV protection is the priority. Both are accessible, well-studied, and supported by branded supply chains.
- If you cannot inject: wait for orforglipron's launch (anticipated 2026–2027). Until then, semaglutide oral (Rybelsus) is the only approved oral GLP-1 — but with restrictive food/water timing and lower efficacy than the injectable.
- If you are already on tirzepatide and stable: the right move in 2026 is rarely to switch. Optimize the rest of the picture (sleep, training, hormones, body composition) before adding more drug or switching molecules.
- If you are aiming for >25% weight loss: retatrutide is the drug to watch. Until launch, tirzepatide at maximum tolerated dose paired with a serious lifestyle and resistance-training architecture is the closest substitute.
- If you are CV-disease-stable: stay on semaglutide unless your physician has a specific reason to switch. The MACE benefit (SELECT trial) is unique to semaglutide so far.
The 2026 landscape, asked and answered.
- Is more weight loss always better?
- No. Beyond a certain point, additional pharmacologic weight loss costs lean mass — which costs longevity. The frontier of this field is now learning to titrate to a target loss and maintain, rather than maximize loss. This is why the TRIUMPH program is studying a 4 mg maintenance dose alongside the 9 mg and 12 mg induction doses.
- Will compounded versions return?
- Almost certainly not for semaglutide and tirzepatide while they remain in adequate supply. Compounded versions only become legal when a drug is on FDA shortage lists. As of May 2026, neither is. Compounded "research-grade" versions sold online are not legal medical products and we do not prescribe from those sources.
- What about microdosing GLP-1s?
- "Microdosing" of GLP-1s is unstudied at the dose ranges patients use it. There is no Phase 3 evidence that doses below the FDA-approved schedule produce durable benefit. We do not microdose unprovably; we may dose conservatively when tolerability requires.
- Will retatrutide actually work in real patients the way TRIUMPH-4 showed?
- Real-world response is consistently lower than trial response — this is true for every drug, not just GLP-1s. Expect retatrutide real-world weight loss to be in the 22–25% range on average, which is still higher than tirzepatide.
- How long do you stay on a GLP-1?
- Indefinite, in most cases — or with a structured taper-and-maintenance plan. Within 12 months of stopping, two-thirds of weight is typically regained without aggressive lifestyle architecture. We treat these drugs as ongoing therapy, like statins or thyroid replacement, for most patients.
Continue the weight-loss series.
The right drug for you depends on more than the headline.
Labs, history, comorbidities, payer access, and goals all factor in. We map your decision against the full landscape — not whichever drug the loudest voice on the internet recommends.
Request a consultation